Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michael R Migden"'
Autor:
Olivia M. Chen, Keemberly Kim, Chelsea Steele, Kelly M. Wilmas, Nader Aboul-Fettouh, Carrick Burns, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3720 (2022)
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, a
Externí odkaz:
https://doaj.org/article/11bfd3d0f3ad403d8e7533dbb66df060
Autor:
Reinhard Dummer, Aaron S. Farberg, Michael R. Migden, Alexander Guminski, Karl D. Lewis, Nicholas Squittieri
Publikováno v:
Dermatology and Therapy
Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and contin
Publikováno v:
Oncotarget
Although basal cell carcinoma (BCC) is often managed successfully with surgery, patients with locally advanced BCC (laBCC) or metastatic BCC (mBCC) who are not candidates for surgery or radiotherapy have limited treatment options. Most BCCs result fr
Publikováno v:
Journal of Drugs in Dermatology. 20:156-165
Basal cell carcinoma (BCC) is the most common malignancy in fair-skinned populations. Most cases are successfully treated with surgery, but in advanced BCCmdash;including locally advanced BCC and metastatic BCCmdash;surgery is likely to result in sub
Autor:
Ruth Plummer, Ralf Gutzmer, Anne Lynn S. Chang, John T. Lear, Martin Kaatz, Uwe Trefzer, Alexandros Stratigos, Carmen Loquai, Luc Dirix, Patrick Combemale, Nicholas Squittieri, Karl D. Lewis, Reinhard Dummer, Michael R. Migden, A Guminksi, Ragini R. Kudchadkar, H.-J. Schulze
Publikováno v:
British Journal of Dermatology. 182:1369-1378
Background: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of t
Autor:
Leonel Hernandez-Aya, Michael R. Migden, Aleksandar Sekulic, Oliver Bechter, Rogerio I. Neves, Kosalai Kal Mohan, Timothy Bowler, Axel Hauschild, Zeynep Eroglu, Ketty Peris, David M. Weinreich, Israel Lowy, Lisa Licitra, Siyu Li, Karl D. Lewis, Jean-François Baurain, Frank Seebach, Marcus O. Butler, Lara Dunn, George D. Yancopoulos, Emily S. Ruiz, Ebony Coates, Anne Lynn S. Chang, Emmanuel Okoye, Matthew G. Fury, Alexander J. Stratigos
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background HHIs, vismodegib and sonidegib, are approved for treatment of patients with mBCC or locally advanced BCC who are not candidates for surgery or radiation. There is no approved option for patients who progress on or are intolerant to HHIs. C
Autor:
Reinhard Dummer, Michael R. Migden, Alexander Guminski, Nicholas Squittieri, John T. Lear, Liang Joo Leow
Publikováno v:
Journal of the American Academy of Dermatology. 84(4)
Publikováno v:
Basal Cell Carcinoma ISBN: 9783030268862
As the most common cancer in humans, basal cell carcinomas (BCCs) affect approximately 2.8 million people. Depending on the location, size, tumor subtype, and other factors, treatment may include topical therapy with imiquimod or 5-fluorouracil, cryo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae665f6b16b80a0c6b1b153280d42f1a
https://doi.org/10.1007/978-3-030-26887-9_13
https://doi.org/10.1007/978-3-030-26887-9_13
Autor:
Nicholas Squittieri, Alexander Guminski, Caroline Robert, Carmen Loquai, James M. Spencer, Felix Kiecker, Aaron S. Farberg, Kurt Gebauer, Reinhard Dummer, Michael R. Migden
Publikováno v:
Journal of the American Academy of Dermatology. 85:AB89
Autor:
Aleksandar Sekulic, Michael R. Migden, Nicole Basset-Seguin, Claus Garbe, Anja Gesierich, Christopher D. Lao, Chris Miller, Laurent Mortier, Dedee F. Murrell, Omid Hamid, Jorge F. Quevedo, Jeannie Hou, Edward McKenna, Natalie Dimier, Sarah Williams, Dirk Schadendorf, Axel Hauschild, for the ERIVANCE BCC Investigators
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
BMC Cancer
BMC Cancer
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic b